The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2016

Filed:

Nov. 26, 2013
Applicant:

Novartis Ag, Basel, CH;

Inventors:

Dale Porter, Cambridge, MA (US);

Caroline Emery, Cambridge, MA (US);

Lujian Tan, Cambridge, MA (US);

Padmaja Yerramilli-Rao, Cambridge, MA (US);

Assignee:

Novartis AG, Basel, CH;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); A61K 31/496 (2006.01); A61K 31/4184 (2006.01); A61K 31/4025 (2006.01); A61K 31/404 (2006.01); A61K 45/06 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 31/404 (2013.01); A61K 31/4025 (2013.01); A61K 31/4184 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01);
Abstract

A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.


Find Patent Forward Citations

Loading…